



**Express Scripts® Pharmacy Benefit Services
Pharmacy and Therapeutics (P&T) Committee
Proceedings
May 21, 2026**

New Drug Evaluations

The Committee reviewed the following new drugs:

- A. Avlayah™ (tvidenofusp alfa-eknm intravenous infusion)** Denali
- B. Awikli® (insulin icodec-abae subcutaneous injection)** NovoNordisk
- C. Idvynso™ (doravirine and islatravir tablets)** Merck
- D. Kresladi™ (marnetegrane autotemcel intravenous infusion)** Rocket
- E. Lifyorli™ (relacorilant capsules)** Corcept Therapeutics
- F. Lynavoy™ (linerixibat tablets)** GlaxoSmithKline
- G. Otarmeni™ (lunsotogene parvec-cwha intracochlear infusion)** Regeneron
- H. Saphnelo® (anifrolumab-fnia subcutaneous injection)** AstraZeneca
- I. Veppanu™ (vepedgestrant tablets)** Pfizer/Arvinas

New Indications for Existing Products

The Committee reviewed the following new or changes to indications for existing products: See product inserts for specific wording.

- A. Alyftrek (vanzacaftor/tezacaftor/deutivacaftor tablets)** Vertex – Expanded indication that broadens eligibility beyond specific variant listings (i.e., F508del), enabling treatment for any gene variant that results in the production of the cystic fibrosis transmembrane regulator (CFTR) protein. Alyftrek is now indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients ≥ 6 years of age who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.
- B. Arexvy (respiratory syncytial virus vaccine [adjuvanted] intramuscular injection)** GlaxoSmithKline – Expanded age indication for adults ≥ 18 years of age who are at increased risk for lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Arexvy is now indicated for active immunization for the prevention of LRTD caused by RSV in individuals 18 years through 59 years of age who are at increased risk of LRTD caused by RSV.
- C. Asceniv (immune globulin intravenous, human – sira [10% Solution])** ADMA – Expanded age indication for primary humoral immunodeficiency (PID) to include patients 2 years to 11 years of age. Asceniv is now indicated for the treatment of PID in adults and pediatric patients ≥ 2 years of age. PID includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
- D. Auvelity (dextromethorphan/bupropion extended-release tablets)** Axsome – New indication for the treatment of agitation associated with dementia due to Alzheimer's disease. Limitation of Use: Auvelity is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease.

- E. Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate inhalation aerosol)** AstraZeneca – New indication for the maintenance treatment of asthma in adults and pediatric patients ≥ 12 years of age.
- F. Cosentyx (secukinumab subcutaneous injection)** Novartis – Expanded age indication to include patients ≥ 12 years of age with hidradenitis suppurativa. Cosentyx is now indicated for the treatment of moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older.
- G. Cosentyx (secukinumab subcutaneous injection)** Novartis – Expanded age indication for ankylosing spondylitis to include patients ≥ 12 years of age. Cosentyx is now indicated for the treatment of active ankylosing spondylitis in adults and pediatric patients ≥ 12 years of age.
- H. Crestor (rosuvastatin tablets)** AstraZeneca – Revised indication to remove specification about no established coronary heart disease and remove the definition of increased risk of cardiovascular (CV) disease. Crestor is now indicated to reduce the risk of major adverse CV events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events. Also, Crestor received another revised indication to include "and exercise" as an adjunctive therapy to reduce low-density lipoprotein cholesterol (LDL-C) and changed hypercholesterolemia to primary hyperlipidemia. Crestor is now indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, and slow the progression of atherosclerosis in adults, and in adults and pediatric patients ≥ 8 years of age with heterozygous familial hypercholesterolemia. Additionally, Crestor was granted a revised indication to remove the specification for use as an adjunct to other LDL-C therapies for homozygous familial hypercholesterolemia and add for use as an adjunct to diet and exercise. Crestor is now indicated as an adjunct to diet and exercise to reduce LDL-C in adults and pediatric patients ≥ 7 years of age with HoFH.
- I. Dupixent (dupilumab subcutaneous injection)** Regeneron/Sanofi – Expanded age indication for pediatric patients ≥ 2 years of age for the treatment of chronic spontaneous urticaria. Dupixent is now indicated for the treatment of chronic spontaneous urticaria in adults and pediatric patients ≥ 2 years of age who remain symptomatic despite H1 antihistamine treatment.
- J. Filspari (sparsentan tablets)** – Traveo) – New indication to reduce proteinuria in adults and pediatric patients ≥ 8 years of age with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
- K. Hadlima (adalimumab-bwwd subcutaneous injection)** Samsung Bioepis – Expanded age indication for hidradenitis suppurativa to include pediatric patients ≥ 12 years of age. Hadlima is now indicated for the treatment of moderate to severe hidradenitis suppurativa in patients ≥ 12 years of age. Additionally, Hadlima received an expanded age indication for uveitis to include pediatric patients ≥ 2 years of age. Hadlima is now indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients ≥ 2 years of age.
- L. Imcivree (setmelanotide subcutaneous injection)** Rhythm – New indication for acquired hypothalamic obesity. Imcivree is now indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged ≥ 4 years of age with acquired hypothalamic obesity.
- M. Keytruda (pembrolizumab intravenous infusion)** Merck and **Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection)** Merck – Revised indication regarding the selection of patients with esophageal or gastroesophageal junction (GEJ) carcinoma. Keytruda and Keytruda Qlex are now indicated for the treatment of patients with locally advanced or metastatic esophageal or GEJ (tumors with epicenter 1 centimeter to 5 centimeters above GEJ) carcinoma that is not amenable to surgical resection or definitive

chemoradiation either in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express programmed death-ligand 1 (PD-L1) [CPS \geq 1] as determined by an FDA-authorized test OR as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS \geq 10) as determined by an FDA-authorized test.

- N. Licart (diclofenac epolamine topical system)** IBSA Pharma – Expanded age indication to include pediatric patients 6 years to < 17 years of age. Licart is now indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients \geq 6 years of age.
- O. Neffy (epinephrine nasal spray)** ARS Pharmaceuticals – Expanded age indication to remove the age limit. Neffy is now indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh \geq 15 kg.
- P. Opdivo (nivolumab intravenous infusion)** Bristol Myers Squibb – New indication for classical Hodgkin lymphoma (cHL) that is previously untreated, Stage III or IV in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients \geq 12 years of age. Also, Opdivo was granted conversion of accelerated approval to traditional approval for relapsed or refractory cHL in adults after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin (Adcetris). Additionally, there was a conversion of accelerated approval to traditional approval for relapsed or refractory cHL in adults after three or more lines of systemic therapy that includes autologous HSCT.
- Q. Stelara (ustekinumab intravenous infusion and subcutaneous injection)** Janssen – Expanded age indication for Crohn's disease to include patients \geq 2 years of age. Stelara is now indicated for moderately to severely active Crohn's disease in adult and pediatric patients \geq 2 years of age.
- R. Symbicort Aerosphere (budesonide and formoterol fumarate inhalation aerosol)** AstraZeneca) – New indication for the treatment of asthma in adults and pediatric patients \geq 12 years of age.
- S. Tecartus (brexucabtagene autoleucel intravenous infusion)** Kite – Conversion of accelerated approval to traditional approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
- T. Trikafta (elexacaftor/tezacaftor/ivacaftor tablets or oral granules and ivacaftor tablets or oral granules)** Vertex – Expanded indication that broadens eligibility beyond specific variant listings (i.e., F508del), enabling treatment for any gene variant that results in the production of the CFTR protein. Trikafta is now indicated for the treatment of CF in adult and pediatric patients \geq 2 years of age who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.
- U. Tzield (teplizumab-mzwv intravenous infusion)** Provention/Sanofi – Expanded age indication for pediatric patients \geq 1 year of age to delay the onset of Stage 3 type 1 diabetes. Tzield is now indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients \geq 1 year of age with Stage 2 type 1 diabetes.
- V. Xpovio (selinexor tablet – Karyopharm)** – Removal of indication for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy in adults.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions:

- A. Atoncy (atomoxetine oral solution)** Validus
- B. Evdi (trabectedin intravenous infusion)** Apotex
- C. Jakafi XR (ruxolitinib extended-release tablets)** Incyte

New Biosimilars

The Committee reviewed the following new biosimilars:

- A. Langlara (insulin glargine-aldy subcutaneous injection)** Sunshine Lake Pharma
- B. Ponlimsi (denosumab-adet subcutaneous injection)** Teva